RenovaCare Issues Important Shareholder Update Following Patent Win and FDA News
RenovaCare, Inc., (RCAR), today announced new initiatives to expand its product pipeline and associated clinical indications beyond severe second-degree burns.
RenovaCare Secures Patent Victory and Continues to Bolster IP Portfolio
RenovaCare, Inc., (RCAR), announced it has decisively won against patent challenger, Avita Medical, in a proceeding at the United States Patent Office (USPTO).
RenovaCare Announces Successful FDA Meeting
RenovaCare (RCAR) announces positive outcomes from its pre-submission meeting with the United States Food and Drug Administration (FDA) regarding the RenovaCare SkinGun™ and CellMist™ Systems.
RenovaCare Issues Stern Response to Admitted Short-Seller, Streetsweeper, Affiliated with Felon Convicted of Securities Fraud
RenovaCare (OTCQB: RCAR) today issued a strong rejection to Streetsweeper, known for spreading “short and distort” commentary on companies it targets for short selling, in this case RenovaCare.
RenovaCare Highlights Clinical Results From 44 Severe Burn Patients Published in Medical Journal
New York, Pittsburgh & Berlin – January 30, 2018 – RenovaCare, Inc., (OTCQB: RCAR), today highlighted an analysis of treatment results from 44 patients treated for severe second-degree wide-area burn injuries, as published in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The treatment method, which involved isolating and spraying the patient’s own skin stem cells on to burn wounds, is the technology underlying the RenovaCare patented SkinGun™* and CellMist™ System*.
RenovaCare 2018 Outlook and Shareholder Update from the CEO
New York, Pittsburgh & Berlin – January 9th, 2018 – RenovaCare, Inc., (OTCQB: RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, is pleased to provide its outlook for 2018, which includes a shareholder update on the Company’s plans to…
RenovaCare Comments On Recent Market Activity
New York & Pittsburgh & Berlin – January 8th, 2018 – RenovaCare, Inc. (“RenovaCare” or the “Company”) (OTCQB: RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that on January 3rd, 2018, OTC Markets Group Inc. (“OTC Markets”)…
RenovaCare SkinGun™ Stem Cell Sprayer on Exhibit at the Science Museum in London
RenovaCare, Inc. today announced the first-ever public display of its breakthrough technology, on exhibit now at the UK’s prestigious Science Museum in London.
RenovaCare Announces Successful Closing of Financing
RenovaCare, Inc. today announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants (the “Warrants”) to purchase…
RenovaCare, Inc. Closes Registered Direct Offering and Concurrent Private Placement
RenovaCare, Inc. today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately 915,000 shares of common stock in a registered direct offering and common stock purchase warrants in a concurrent private placement…